Alveron Pharma raises a further EUR 3.9 million to progress first in class cyclodextrin drug

Posted by

Alveron Pharma BV (Nijmegen, The Netherlands) has raised a further EUR 3.9 million to fund the continued development of OKL-1111, a first-in-class drug to treat anticoagulant related bleeds. Investors Thuja Capital, Waterman Ventures and Oost NL participated in the fund raising alongside a loan from Rijksdienst Voor Ondernemend Nederland (RVO). The round follows seed financing of EUR 6.5 million in 2019.

The additional funding will finance the OKL-1111 program including a first in man study which is anticipated to start in Q3 2022.

Alveron’s drug is unique as it reverses the effects of all the major anticoagulants (including all DOACs and vitamin K antagonists) and platelet aggregation inhibitors like clopidogrel. This enables clinicians to intervene in emergencies without prior knowledge of the type of anticoagulant used and potentially simplifies treatment protocols. The drug, in contrast to leading competitors, is not a biologic nor a blood derived material, providing both cost and safety advantages.

According to the patent of the company (WO2017188820A1) OKL-1111 is one of substituted cyclodextrins comprising at least one substituent -S-(Cn-alkylene)-R and pharmaceutically acceptable salts thereof, pharmaceutical compositions, kits of parts and their use as procoagulants. The invention further relates to said cyclodextrins for use in methods of reversing an anticoagulant effect of an anticoagulant in a subject, in methods for reducing or preventing bleeding in a subject and in methods for the treatment or prevention of a blood coagulation disorder.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.